NCT02869802Recruiting
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 190 (estimated)
- First submitted
- 9 Aug 2016
- Start date
- 6 Oct 2016
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- British Columbia Cancer Agency
- Diseases
- Pancreatic cancer
- NCT number
- NCT02869802
What you commit to
- Study type: Observational
- Planned participants: 190
- From 6 Oct 2016 to the primary completion date, 31 Dec 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received prior systemic therapy (chemotherapy or any other anti-cancer agent) in the advanced setting. Patients who received adjuvant chemotherapy after surgical resection of early stage disease are eligible.
- Currently receiving anti-cancer therapy (chemotherapy or any other anti-cancer agent)
- Not fit for combination chemotherapy as judged by the investigator
Other
- Absence of distant or lymph node metastases. Patients with borderline resectable or locally advanced PDAC are not eligible.
- Presence of brain metastases
- Female patients with positive pregnancy test
- Patients who are not safe to include in the study as judged by the investigator for any medical or non-medical reason
- Unable to comply with study assessments and follow-up
Who the study is looking for
- Histological and/or radiological diagnosis of metastatic PDAC. Patients without a histological diagnosis of PDAC must undergo confirmatory tumour biopsy prior to treatment start date.
- Planned for first-line systemic therapy with FOLFIRINOX or GP, either in routine care or in combination with an investigational agent(s) within a clinical trial.
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate organ function
- Life expectancy of \> 90 days as judged by the investigator
- Ability to give informed consent
- Measurable disease by RECIST 1.1
- Presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist. A minimum of 3 tumour cores must be safely obtainable under CT or US guidance.
- Fit enough to safely undergo a tumour biopsy as judged by the investigator
- Ability to lie supine for \> 60 minutes
- Patients in the archival cohort must also fulfil the following criteria:
- Archival tumour sample available (either a previous tumour diagnostic biopsy or resection specimen)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tom Baker Cancer Centre Coordinator of this site? Confirm its status | Calgary | Canada | Completed |
| Cross Cancer Institute Coordinator of this site? Confirm its status | Edmonton | Canada | Withdrawn |
| The Ottawa Hospital Coordinator of this site? Confirm its status | Ottawa | Canada | Active, not recruiting |
| BC Cancer - Vancouver Coordinator of this site? Confirm its status | Vancouver | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.